Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation : A case report
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Tyrosine kinase inhibitors (TKI) have been the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) of epidermal growth factor receptor (EGFR) sensitive mutations. Uncommon EGFR mutations are increasingly reported with the development of next-generation sequencing. However, their sensitivity to TKIs is variable with limited clinical evidence.
CASE SUMMARY: Here, we report a patient with the rare delE709_T710insD mutation, who showed the favorable efficacy of dacomitinib and achieved a partial response with a progression-free survival of 7.0 mo.
CONCLUSION: To our knowledge, this is the first report displaying the clinical efficacy of dacomitinib for patients with delE709_T710insD, which may help to provide alternatives in non-classical variant NSCLC patients. Further studies are warranted to make the optimal choice of EGFR-TKI for rare mutations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
World journal of clinical cases - 10(2022), 17 vom: 16. Juni, Seite 5916-5922 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Fei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 19.08.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12998/wjcc.v10.i17.5916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344977323 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344977323 | ||
| 003 | DE-627 | ||
| 005 | 20231226024016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12998/wjcc.v10.i17.5916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344977323 | ||
| 035 | |a (NLM)35979118 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Fei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation |b A case report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Tyrosine kinase inhibitors (TKI) have been the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) of epidermal growth factor receptor (EGFR) sensitive mutations. Uncommon EGFR mutations are increasingly reported with the development of next-generation sequencing. However, their sensitivity to TKIs is variable with limited clinical evidence | ||
| 520 | |a CASE SUMMARY: Here, we report a patient with the rare delE709_T710insD mutation, who showed the favorable efficacy of dacomitinib and achieved a partial response with a progression-free survival of 7.0 mo | ||
| 520 | |a CONCLUSION: To our knowledge, this is the first report displaying the clinical efficacy of dacomitinib for patients with delE709_T710insD, which may help to provide alternatives in non-classical variant NSCLC patients. Further studies are warranted to make the optimal choice of EGFR-TKI for rare mutations | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Dacomitinib | |
| 650 | 4 | |a DelE709_T710insD | |
| 650 | 4 | |a Next-generation sequencing | |
| 650 | 4 | |a Non-small-cell lung cancer | |
| 650 | 4 | |a Uncommon EGFR mutation | |
| 700 | 1 | |a Xia, Meng-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Hui-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Jiong-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yi-Hong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of clinical cases |d 2013 |g 10(2022), 17 vom: 16. Juni, Seite 5916-5922 |w (DE-627)NLM233331727 |x 2307-8960 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:17 |g day:16 |g month:06 |g pages:5916-5922 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12998/wjcc.v10.i17.5916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 17 |b 16 |c 06 |h 5916-5922 | ||